ACXP (Acurx Pharmaceuticals) Beginning Cash Position: $9.25 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACXP Acurx Pharmaceuticals Inc ACXP
37 GF Score
Price $1.44
View Full Analysis

What is Acurx Pharmaceuticals Beginning Cash Position?

Acurx Pharmaceuticals ACXP +0.70% 37 Beginning Cash Position is $9.25 Mil as of Jun. 2026. GuruFocus rates ACXP with a GF Score™ of 37/100.

Acurx Pharmaceuticals's Beginning Cash Position for the quarter that ended in Jun. 2026 was $9.25 Mil.

Acurx Pharmaceuticals's quarterly Beginning Cash Position increased from Dec. 2025 ($5.91 Mil) to Mar. 2026 ($7.56 Mil) and increased from Mar. 2026 ($7.56 Mil) to Jun. 2026 ($9.25 Mil).

Acurx Pharmaceuticals's annual Beginning Cash Position declined from Dec. 2023 ($9.11 Mil) to Dec. 2024 ($7.47 Mil) and declined from Dec. 2024 ($7.47 Mil) to Dec. 2025 ($3.71 Mil).

Acurx Pharmaceuticals Beginning Cash Position Related Terms

Acurx Pharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Acurx Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acurx Pharmaceuticals Beginning Cash Position Chart

Acurx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 3.18 12.96 9.11 7.47 3.71

Acurx Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.64 6.06 5.91 7.56 9.25
ACXP
37GF Score
Acurx Pharmaceuticals Inc ACXP
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acurx Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $9.25 Mil mean?
Acurx Pharmaceuticals (ACXP) has a Beginning Cash Position of $9.25 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Acurx Pharmaceuticals and its competitors.
Is Acurx Pharmaceuticals' Beginning Cash Position too high?
Acurx Pharmaceuticals' current Beginning Cash Position is $9.25 Mil. Overall, Acurx Pharmaceuticals has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Acurx Pharmaceuticals' Beginning Cash Position compare to ENVB and HCWB?
Acurx Pharmaceuticals' Beginning Cash Position of $9.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Acurx Pharmaceuticals and its competitors. Acurx Pharmaceuticals's current Beginning Cash Position is $9.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acurx Pharmaceuticals stock overvalued right now?
Acurx Pharmaceuticals (ACXP) has a current Beginning Cash Position of $9.25 Mil. The current Beginning Cash Position is $9.25 Mil. Acurx Pharmaceuticals' overall GF Score™ is 37/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Acurx Pharmaceuticals (ACXP), the current Beginning Cash Position is $9.25 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acurx Pharmaceuticals Business Description

Address 259 Liberty Avenue, Staten Island, NY, USA, 10305
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
37GF Score

Get the complete analysis for ACXP

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.44
Price